Evommune's EVO756 fails Phase 2b atopic dermatitis trial, shifts focus to EVO301Sep 8Clinical readoutEVO756Evommune, Inc.
Evommune reports Q2 2026 results, sets EVO756 AD data for SeptemberAug 6Quarterly updateEVO756Evommune, Inc.
Evommune doses first patient in Phase 2b trial of EVO756 for migraine preventionJul 30Clinical readoutEVO756Evommune, Inc.
Evommune's EVO756 fails primary endpoint in Phase 2b urticaria trialJun 29Clinical readoutEVO756Evommune, Inc.
Sign inSign in